No Data
No Data
Cathie Wood's Ark Invest Is Buying the Dip on Tech Stocks
Express News | Tempus AI Announces Publication Of HLA-LOH Investigational Assay Validation Study In Npj Precision Oncology; Study Demonstrates Detection Of HLA Loss Of Heterozygosity Using Tempus' FDA-Approved XT CDx Assay For Prognostic And Therapeutic...
NPJ Precision Oncology Publishes Tempus Study on Validation of Its HLA-LOH Investigational Assay
Tempus AI Is Maintained at Overweight by JP Morgan
Express News | JP Morgan Maintains Overweight on Tempus AI, Raises Price Target to $47
Express News | Tempus AI Shares Down 2.9% Premarket After Q2 Results
No Data